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Introduction
============

Sepsis is characterised by a bewildering array of abnormalities in both innate and adaptive immune systems. To help explain this complex pathophysiology, a two-phase model has been used by investigators. This model postulates that sepsis consists of an initial phase of systemic inflammatory response syndrome, followed by a later phase of compensatory anti-inflammatory response syndrome. This two-phase model has been the reigning paradigm under which scientists develop new therapeutic agents, with new drugs targeting either the pro-inflammatory or the anti-inflammatory arm of the host response. However, clinical trials have consistently failed to demonstrate any survival benefit of drugs that target the inflammation pathway. As a result, concerns have been raised regarding the validity of treating sepsis simply as a pro-inflammatory or anti-inflammatory phenomenon.

Complicating this uncertainty is the limited evidence to verify the two-phase model. Cytokine studies have been the mainstay evidence that provide support for the inflammation-based model. However, increasingly conflicting findings have emerged from recent cytokine studies \[[@B1]-[@B3]\]. Furthermore, it is often difficult to determine the exact nature of the host response (for example, pro-inflammatory versus anti-inflammatory) on the basis of cytokine measurement alone, which is highly variable depending on the choice of the cytokine used and the timing of the measurements.

Given the limitations of the protein level studies, we assessed the validity of the inflammation-based model using transcriptional level data. Genome-wide transcriptional studies have recently emerged as a powerful investigational tool to study complex disease \[[@B4]\]. These studies avoid the selection bias inherent in most cytokine studies, where only a small number of pre-selected genes can be examined. In this systematic review, we synthesized genomic data of recent microarray studies where the transcriptional changes of circulating leukocytes were examined in both experimental and clinical sepsis in humans.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

We searched in Medline and Embase, without language restriction, all publications on gene-expression studies between January 1987 and October 2010. In 1987 DNA array technology was first described, hence this year formed the starting point of our search \[[@B5]\]. We hand-searched the reference lists of every primary study for additional publications. Further searches were performed by reviewing journal editorials and review articles.

The search strategy used the following search terms: (1) \"gene-expression profiling\", (2) \"microarray analysis\", (3) \"transcription profiling\", (4) \"cluster analysis\", (5) \"Affymetrix\", (6) \"GeneChip\", (7) \"sepsis\", (8) \"sepsis syndrome\", (9) \"septicaemia\", (10) \"bacteraemia\", (11) \"septic shock\", (12) \"infection\", (13) \"systemic inflammatory response syndrome\", (14) \"SIRS\", (15) \"systemic inflammation\", (16) \"endotoxin\".

We also performed searches in public repositories of microarray datasets, including the National Centre for Biotechnology Information (Gene Expression Omnibus), the European Bioinformatics Institute (ArrayExpress), and the Centre for Information Biology Gene Expression Database (CIBEX). Datasets from microarray database were then cross-referenced with publications retrieved from Medline and Embase. Only datasets published as full reports were included in the final analysis.

We included a broad spectrum of gene-expression studies, including ones that are (1) cross-sectional or longitudinal design, (2) on different microarray platforms, (3) on whole blood or purified leukocytes, (4) in healthy volunteers or infected human hosts, and (5) paediatric or adult patients. As we only sought data on a genome-wide scale, we have excluded studies that assayed only a small number of genes, such as (1) Northern blot or PCR, (2) single gene or individual pathway studies, (3) proteomic studies, and (4) single-nucleotide polymorphism studies. We included custom designed microarrays only if such arrays are designed to study changes in inflammation pathways. Since we were interested in host response on a systematic level, as reflected by circulating leukocytes, we have excluded studies that (1) focused on resident immune cells such as alveolar macrophages or lymphoid tissue cells, and (2) used solid organ tissues such as spleen or liver.

Data extraction
---------------

We extracted study level data according to a pre-specified template, which included participant demographics, country of origin, clinical setting and inclusion criteria. A separate template was used to collect details of microarray experiments, including sample collection procedures, cell separation techniques, target cell types, methods used to extract ribonucleic acids, cDNA synthesis and hybirdization, microarray platforms used, number of probe set on arrays, microarray data processing and normalization methods. We extracted the signature gene list from each published report or from the accompanied data file in the journal websites. Where available, results of functional analyses were also extracted. These included results of cluster analyses, principle component analyses or pathway analyses.

Quality assessment
------------------

We performed a quality assessment of each study based on criteria modified from published guidelines on the statistical analysis and reporting of microarray data \[[@B6]\]. The assessment was performed using a 14-item checklist covering three quality domains including data acquisition (three items), statistical analysis (six items) and validation of microarray findings (five items).

Data synthesis
--------------

We performed a narrative synthesis on genomic data extracted from each study. First, individual genes from the gene list of primary studies were manually annotated by cross-referencing with publicly available gene nomenclatures databases (for example, Genebank, Locuslink, Affymetrix gene identifiers). Where a gene list was not available, findings on functional analyses reported by the original authors were used. These included cluster analysis or gene network analysis performed on the original microarray data. All results were then collated and presented in evidence tables. Due to the heterogeneous nature of the included studies, meta-analysis of the microarray data was not performed.

Results
=======

The literature search yielded 7,548 citations in electronic databases and 142 datasets in microarray data repositories. Of these, 12 patient cohorts met the inclusion criteria and were included in the final analysis (Figure [1](#F1){ref-type="fig"}).

![**Study selection**.](cc9392-1){#F1}

Clinical characteristics of the included studies are summarized in Table [1](#T1){ref-type="table"}. The cohorts were drawn from a broad spectrum of clinical settings including hospital wards, intensive care units and university research centres. The majority of the study participants were critically ill patients diagnosed with sepsis or infection. Among patients with sepsis, a full range of sepsis syndrome was represented (for example, sepsis, severe sepsis and septic shock).

###### 

Summary of studies characteristics

                           **Prucha**\[[@B14]\]    **Tang-1**\[[@B15],[@B16]\]   **Ramilo**\[[@B17]\]    **Tang-2**\[[@B18]\]    **Talwar**\[[@B8]\]   **Payen**\[[@B19]\]     **Cobb**\[[@B20],[@B21]\]   **Pachot**\[[@B22]\]   **Prabhakar**\[[@B9]\]   **Calvano**\[[@B10]\]   **Wong**\[[@B23]-[@B26]\]   **Johnson**\[[@B27],[@B28]\]
  ------------------------ ----------------------- ----------------------------- ----------------------- ----------------------- --------------------- ----------------------- --------------------------- ---------------------- ------------------------ ----------------------- --------------------------- ------------------------------
  **Aims**                 Diagnostic prediction   Diagnostic prediction         Diagnostic prediction   Diagnostic prediction   Functional analysis   Prognostic study        Prognostic study            Prognostic study       Functional analysis      Functional analysis     Combined analysis^¥^        Functional analysis
  **Study design**         Cross-sectional         Cross-sectional               Cross-sectional         Cross-sectional         Longitudinal          Longitudinal            Longitudinal                Cross-sectional        Longitudinal             Longitudinal            Longitudinal                Longitudinal
  **Country**              Czech Rep..             Australia                     U.S.A.                  Australia               U.S.A.                France                  U.S.A.                      France                 U.S.A.                   U.S.A.                  U.S.A.                      U.S.A.
  **Total (n)**            12                      94                            148                     70                      12                    17                      176                         38                     12                       14                      101                         90
  **Mean Age (yr)**        58.9                    63.5                          3.4                     65.5                    30                    59                      35.7                        67                     (18 to 40)^†^            (18 to 40)^†^           3.2                         44
  **Clinical setting**     Adult ICU               Adult ICU                     Pediatric wards         Adult ICU               University clinic     Adult ICU               Adult ICU                   Adult ICU              University clinic        University clinic       Pediatric ICU               Trauma ICU
  **Inclusion criteria**   Severe sepsis           Sepsis                        Acute infection         Sepsis                  Healthy volunteers    Septic shock            Post-trauma                 Septic shock           Healthy volunteers       Healthy volunteers      Sepsis                      SIRS
  **Control group**        Surgical patients       SIRS patients                 Healthy subjects        SIRS patients           Healthy subjects      Subjects at time zero   Non-septic patients         NA                     Subjects at time zero    Healthy subjects        Non-septic patients         SIRS patients

SIRS denotes systemic inflammatory response syndrome. ICU denotes intensive care unit. NA denotes not applicable.

^†^Mean age not available. ^¥^Both functional analysis and diagnostic prediction.

Details of the microarray experiments are summarized in Tables [2](#T2){ref-type="table"}. The target tissue was either whole blood or purified leukocytes isolated from whole blood (for example, neutrophils or mononuclear cells). Affymetrix was the most common microarray platform used. In total, gene-expression profiling of 784 individuals were performed across four different microarray platforms.

###### 

Microarray experiments in included studies

                                   **Prucha**\[[@B14]\]   **Tang-1**\[[@B15],[@B16]\]   **Ramilo**\[[@B17]\]   **Tang-2**\[[@B18]\]   **Talwar**\[[@B8]\]   **Payen**\[[@B19]\]   **Cobb**\[[@B20],[@B21]\]   **Pachot**\[[@B22]\]   **Prabhakar**\[[@B9]\]   **Calvano**\[[@B10]\]   **Wong**\[[@B23]-[@B26]\]   **Johnson**\[[@B27],[@B28]\]
  -------------------------------- ---------------------- ----------------------------- ---------------------- ---------------------- --------------------- --------------------- --------------------------- ---------------------- ------------------------ ----------------------- --------------------------- ------------------------------
  **[Experiment details]{.ul}**                                                                                                                                                                                                                                                                                   
  **Tissue used**                  Whole blood            Neutrophils                   PBMC                   PBMC                   PBMC                  PBMC                  PBMC                        Whole blood            PBMC                     Whole blood             Whole blood                 Whole blood
  **RNA extraction**               PAXGene                Ambion                        Qiagen                 Ambion                 Qiagen                Qiagen                Qiagen                      PAXGene                Qiagen                   Qiagen                  PAXGene                     PAXGene
  **Microarray platform**          Lab-Arraytor           In-house                      Affymetrix             Affymetrix             Affymetrix            Lab-Arraytor          Affymetrix                  Affymetrix             In-house                 Affymetrix              Affymetrix                  Affymetrix
  **No. of genes or probe sets**   340                    18,664                        14,500                 54,675                 12,623                340                   54,613                      14,500                 18,432                   33,000                  54,675                      54,675
  **[Signature genes]{.ul}**                                                                                                                                                                                                                                                                                      
  **Sepsis vs. control**           50                     50                            137                    138                    867                                         1,837                                              54                       3,714                   1,906                       459
  **Survival vs. death**                                                                                                                                    10                                                28                                                                                                  

^¶^Signature genes were searched but not found.

RNA denotes ribonucleic acid. G-Pos/Neg denotes Gram-Positive sepsis or Gram-Negative sepsis. PBMC denotes peripheral blood mononuclear cells.

Results on the assessment of the methodological quality of each microarray study are presented in Table [3](#T3){ref-type="table"}. Just over half of the studies fulfilled the MIAMI criteria (Minimum Information About Microarray Experiment, published guidelines on the design, conducting, analysis and reporting of the microarray experiments) \[[@B7]\]. Only seven studies performed internal validation of microarray data and independently validated their reported gene lists in separate data sets. Raw microarray data are available in only 7 out of the 12 cohorts.

###### 

Methodological quality of microarray experiments

                                               **Prucha**\[[@B14]\]   **Tang-1**\[[@B15],[@B16]\]   **Ramilo**\[[@B17]\]   **Tang-2**\[[@B18]\]   **Talwar**\[[@B8]\]   **Payen**\[[@B19]\]   **Cobb**\[[@B20],[@B21]\]   **Pachot**\[[@B22]\]   **Prabhakar**\[[@B9]\]   **Calvano**\[[@B10]\]   **Wong**\[[@B23]-[@B26]\]   **Johnson**\[[@B27],[@B28]\]
  -------------------------------------------- ---------------------- ----------------------------- ---------------------- ---------------------- --------------------- --------------------- --------------------------- ---------------------- ------------------------ ----------------------- --------------------------- ------------------------------
  **[Data acquisition]{.ul}**                                                                                                                                                                                                                                                                                                 
  Tissue homogeneity of target samples         Low                    High                          High                   High                   High                  High                  High                        Low                    High                     Low                     Low                         High
  Experiments follow miame criteria^¶^         Yes                    Yes                           Yes                    Yes                    Not clear             Yes                   Not clear                   Not clear              Not clear                Not clear               Yes                         Not clear
  Reporting of normalization method            No                     Yes                           Yes                    Yes                    Yes                   Yes                   Yes                         Yes                    No                       Yes                     Yes                         Yes
  **[Analytical issues]{.ul}**                                                                                                                                                                                                                                                                                                
  Method for gene selection                    *t*test                *t*test                       Non-parametric test    *t*test                ANOVA                 *t*test               Multiple                    Not clear              Not clear                SAM                     ANOVA and fold change       Non-parametric test
  Issue of variance estimation addressed       No                     Yes                           No                     Yes                    No                    No                    Not clear                   Not clear              Not clear                Yes                     No                          No
  Comparison to other diagnostic markers       No                     No                            No                     No                     No                    NA                    Yes                         Yes                    No                       No                      No                          Yes
  Correction for multiple testing              Yes                    Yes                           Yes                    Yes                    Yes                   NA                    Yes                         Yes                    No                       Yes                     Yes                         Yes
  Reporting of classifier performance          No                     Yes                           No                     Yes                    NA                    NA                    No                          Yes                    NA                       NA                      Yes                         NA
  Reporting of prediction accuracy             No                     Yes                           Yes                    Yes                    NA                    NA                    Yes                         Yes                    NA                       NA                      Yes                         NA
  **[Validation of data]{.ul}**                                                                                                                                                                                                                                                                                               
  Cross validation of signature genes          No                     Yes                           Yes                    Yes                    No                    No                    Yes                         Yes                    NA                       No                      Yes                         Yes
  External validation in independent samples   No                     Yes                           Yes                    Yes                    No                    No                    Yes                         Yes                    NA                       Yes                     Yes                         No
  Ratio of test/training sample size           NA                     1.14                          2.00                   1.00                   NA                    NA                    0.50                        0.23                   NA                       0.75                    0.77                        NA
  Adjustment for confounders                   No                     Yes                           Yes                    No                     NA                    NA                    No                          No                     No                       NA                      Yes                         Yes
  Raw data made publicly available             No                     Yes                           Yes                    Yes                    Yes                   Yes                   No                          No                     No                       No                      Yes                         No
  PCR validation                               Yes                    No                            Yes                    Yes                    Yes                   Yes                   Yes                         Yes                    Yes                      No                      No                          Yes

Minimum Information About Microarray Experiment checklist \[[@B7]\]. ANOVA denotes analysis of variance. SAM denotes Significance Analysis of Microarrays \[[@B29]\].

NA denotes not applicable.

A wide range of statistical approaches were used by the included studies. Table [3](#T3){ref-type="table"} provides detailed information on the reporting of the statistical methods by each study. Most studies provided details on the method used for normalization. Normalization is a data processing method that ensures only genes, which are truly differentially expressed between phenotypes of interest, are detected, instead of those caused by experimental artefacts or variation in the microarray hybirdization process. Different statistical approaches were used for detecting statistically significant genes, depending on the study design used in each cohort (Table [3](#T3){ref-type="table"}). Multiple testing corrections were used by most studies to minimize a false positive rate in the significant genes (Table [3](#T3){ref-type="table"}). However, variance estimation was poorly reported in most studies. A variety of variance estimation techniques were used by the included studies; but details were lacking in most studies (conventional *t*-statistics based variance estimation methods under-estimate the true variance of microarray data, so several variance estimation methods for microarray data have been developed). Overall, the reporting of statistical methods was variable among studies.

Pathogen recognition
--------------------

Sepsis activates pathogen recognition pathways in host leukocytes. This is evident in most studies. Up-regulation of pathogen recognition receptors, such as toll-like receptors and CD14, was observed (Table [4](#T4){ref-type="table"}). This was accompanied by the activation of signal transduction pathways, a process essential for subsequent transcription of immune response genes. The signal transduction pathways include nuclear factor kappa-B (NK-kβ), mitogen activated protein kinase (MAPK), Janus kinase (JAK) and transducer and activator of transcription protein (STAT) pathways (Table [4](#T4){ref-type="table"}). The up-regulation of both pathogen recognition and signal transduction pathway genes was observed in most cohorts, including experimental and clinical sepsis, paediatric and adult patients, early and late sepsis.

###### 

Gene-expression changes in pathogen recognition

                                 Pathogen recognition                                             Signal transduction
  ------------------------------ ---------------------------------------------------------------- --------------------------------------------------------------------------------------------
  **Johnson**\[[@B27],[@B28]\]   Increase expression in toll-like receptor (TLR) pathway genes.   Increased expression in pathways genes associated with NF-*k*B, STAT, JAK and MAPKs.
  **Talwar**\[[@B8]\]            Increase expression in TLR pathway genes.                        Increased expression in genes associated with STAT, JAK and MAPKs pathways.
  **Calvano**\[[@B10]\]          Increase expression in TLR pathway genes and CD14 genes.         Increased expression in genes associated with STAT, NF-*k*B, CREB, JAK and MAPKs pathways.
  **Prabhakar**\[[@B9]\]         Increase expression in genes encoding for CD14 molecules.        Increased expression in genes associated with JAK pathway.
  **Prucha**\[[@B14]\]                                                                            Increased expression in genes associated with MAPKs pathway.
  **Tang-1**\[[@B15],[@B16]\]                                                                     Reduced expression in pathways genes associated with NF-*k*B and MAPKs pathways.
  **Tang-2**\[[@B18]\]           Increase expression in TLR pathways genes.                       Increased expression in genes associated with JAK, STAT and MAPKs pathways.
  **Cobb**\[[@B20],[@B21]\]                                                                       Increased expression in genes associated with MAPKs pathway.
  **Wong**\[[@B23]-[@B26]\]      Increase expression in TLR pathways genes.                       Increased expression in genes associated with NF-*k*B STAT and MAPKs pathways.
  **Payen**\[[@B19]\]            Increase expression in TLR pathways genes in survivors.          Greater expression of genes associated with MAPKs pathway in non-survivors.
  **Pachot**\[[@B22]\]           Increase expression in TLR pathways genes in survivors.          Greater expression of genes associated with MAPKs pathway in non-survivors.

**Abbreviations**; NF-ĸB denotes nuclear factor kappa-B, MAPKs denotes mitogen activated protein kinase, JAK denotes Janus Kinase, STAT denotes transducer and activator of transcription protein, CREB denotes cAMP responsive element binding protein, TLR denotes toll-like receptor.

Inflammatory response
---------------------

In contrast to the above findings, changes in inflammatory pathways were much less consistent. A distinctive pro-inflammatory or anti-inflammatory phase, as depicted in the classic sepsis model, was not seen during any stage of sepsis. The early, transient rise in some pro-inflammatory mediators was evident only in a minority of studies (Table [5](#T5){ref-type="table"}). In some studies, the expression of anti-inflammatory genes dominated over pro-inflammatory genes. In others, changes in inflammatory genes were noticeably absent. No studies demonstrated a clear transition from a pro-inflammatory phase to an anti-inflammatory phase during the course of sepsis. Overall, the transcriptional changes in inflammation-related genes are highly variable in most cohorts.

###### 

Gene-expression in inflammation and immunity

                                 Timing                                             Gene-expression                                       Overall effect                                                                               Changes in inflammatory and immune genes
  ------------------------------ -------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Johnson**\[[@B27],[@B28]\]   Pre-sepsis (12 to 36 hrs prior to the diagnosis)   ↑394 genes and ↓65 genes                              Activation of host response to infection.                                                    Increased expression of genes associated with pro-inflammatory cytokines (IL-1, IL-18), immune cell receptor signalling (IFNR, IL-10RA, TNFSF) and T cell differentiation (IFNGR, IL-18R, IL-4R).
                                                                                                                                          Activation of counter-regulatory mechanism that limits the pro-inflammatory response.        Increased expression of genes that limit pro-inflammatory cytokines (SOCS3).
  **Talwar**\[[@B8]\]            Early Sepsis (0 to 24 hrs)                         ↑439 genes and ↓428 genes                             Activation of host response to infection.                                                    Increased expression of genes associated with cytokines (IL-1R, CCR1, CCR2, IL-17) and S100 calgranulins (S100A12, S100A11, S100A9, S100A8). Increased expression of genes associated with arachidonate metabolites (ALOX5) and anti-pathogen oxidases (CYBA, SOD)
                                                                                                                                          Activation of counter-regulatory mechanism that limits the pro-inflammatory response.        Increased expression of anti-inflammatory cytokines (IL-1RA, IL-10R) and reduced expression of pro-inflammatory genes (TNFSFR).
                                                                                                                                          Repression of immune cells and host defence, including antigen presentation by phagocytes.   Reduced expression of genes associated with T cells, cytotoxic lymphocytes and natural killer cells (T cell receptor, CD86, IL-2 receptor, TNFRSF7, CD160, cathepsin, CCR7, CXCR3, CD80). Reduced expression in MHC class II genes.
  **Calvano**\[[@B10]\]          Early Sepsis (0 to 24 hrs)                         ↓ more than 1,857 (\>50%)^¶^                          Activation of host response to infection.                                                    Increased expression of genes associated with pro-inflammatory cytokines (TNF, IL-1, IL-1A, IL-1B, IL-8, CXCL1, CXCL10).
                                                                                                                                                                                                                                       Increased expression of genes associated with superoxide-producing activities and cell-cell signalling.
                                                                                                                                          Activation of counter-regulatory mechanism that limits the pro-inflammatory response.        Increased expression of genes that limit the inflammatory response (SOSC3, IL1-RAP, IL1-R2, IL10 and TNFRSF1A).
                                                                                                                                          Repression of immune cells and host defence, including antigen presentation by phagocytes.   Reduced expression of genes associated with immune response in lymphocytes (TNFRSF7, CD86, CD28, IL-7R, lL-2RB).Reduced expression in MHC class II genes.
  **Prabhakar**\[[@B9]\]         Early Sepsis (0 to 24 hrs)                         ↑31 genes and ↓23 genes                               Activation of host response to infection.                                                    Increased expression of pro-inflammatory genes (IL-1B, TRAIL) and S100 calgranulins. Increased expression of genes associated arachidonate metabolites (ALOX5, SOD).
                                                                                                                                          Activation of counter-regulatory mechanism that limits the pro-inflammatory response.        Increased expression of genes associated with cytokine suppression (SOCS1, SOCS3).
                                                                                                                                          Reduced antigen presentation by phagocytes.                                                  Reduced expression in MHC class II genes.
  **Prucha**\[[@B14]\]           Late-sepsis (1 to 5 days)                          ↑19 genes and ↓31 genes                               Diminished pro-inflammatory response.                                                        Increase expression of pro-inflammatory genes (IL-18, S100A8, S100A12), but reduced expression in others (TNF, IL8RA, CASP5, IL-6ST).
                                                                                                                                          Enhanced anti-inflammatory response.                                                         Increased expression of anti-inflammatory genes (TGFβ1).
                                                                                                                                          Reduced lymphocyte function and antigen presentation by phagocytes.                          Reduced expression of genes associated with lymphocyte function (IL-16, CD69, CD8, CD36, CX3CR1). Reduced expression in MHC class II genes.
  **Tang-1**\[[@B15],[@B16]\]    Late-sepsis (1 to 5 days)                          ↑35 genes and ↓15 genes                               Diminished pro-inflammatory response.                                                        Reduced expression of pro-inflammatory genes (TNF, IL8RA, CASP5)
                                                                                                                                          Reduced immune cell function.                                                                Reduced expression of genes that modulate immune cell activation (IL-16, CD69, CD8, CD36).
  **Tang-2**\[[@B18]\]           Late-sepsis (1 to 5 days)                          ↑105 genes and ↓33 genes                              Diminished pro-inflammatory response.                                                        Reduced expression of pro-inflammatory genes (TNFSF8), S100 calgranulins S100A8) and IL-4 pathway.
                                                                                                                                          Increased anti-inflammatory response.                                                        Increased expression of anti-inflammatory genes (IL-10RB, TGFβ1).
                                                                                                                                          Reduced antigen presentation by phagocytes.                                                  Reduced expression in MHC class II genes.
  **Wong**\[[@B23]-[@B26]\]      Late-sepsis (1 to 5 days)                          ↑862 gene and ↓1,283 genes (Day 1)                    Activation of both pro-inflammatory and anti-inflammatory response.                          Increased expression of both pro-inflammatory (IL-1 and IL-6) and anti-inflammatory (IL-10, TGFβ1) genes. Increased expression of genes associated with receptor signalling and granulocyte colony stimulating factor.
                                                                                    ↑1,072 gene and ↓1,432 genes (Day 3)                  Repression of immune cells and host defence, including antigen presentation by phagocytes.   Reduced expression of genes associated with antigen presentation, immune cell activation, IL-8 and IL-4 pathways.
                                                                                                                                                                                                                                       Reduced expression in MHC class II genes.
  **Cobb**\[[@B20],[@B21]\]      Late sepsis (1 to 5 days)                          1,837 genes                                           Unclear as only a small subset of genes are available for analysis.                          Increased expression of pro-inflammatory genes (IL-1beta, NAIP, CEACAM8, and the alpha-defensins).
  **Payen**\[[@B19]\]            Recovery (\>5 days)                                ↑1 gene and ↓3 genes (survivors).                     Ongoing immuno-suppression throughout the 28-day study period.                               In survivors, there was a progressive reduction in the expression of genes associated with S100 calgranulins (S100A8 and S100A12) and T cell activation (IL-3RA).
                                                                                    ↑29 gene and ↓7 genes (non-survivors).                Greater extent of immuno-suppression in non-survivors.                                       In non-survivors, there was an even greater reduction in the expression of genes associated with immune cell activation (CXCL14, CD180, CD244, CCR6 and CD84). In the same patients, there was also an increase expression of apoptosis genes (PPARG, DAP3 and HBXIP) and anti-inflammatory genes (PAFAH1B1 and IL-4R).
                                                                                                                                          Survival is accompanied with recovery of some immune functions.                              Recovery of MHC class II gene (CD74) in survivors occurs on day 28.
  **Pachot**\[[@B22]\]           Recovery (\>5 days)                                ↑18 genes (survivors) and ↑10 genes (non-survivors)   Survival in sepsis is associated with restoration of immune function.                        In survivors, there was an increased expression of genes in modulating T cell activation and receptor signalling (ILRB2, CXC31, TRDD3, TIAM1, FYN).

↑ denotes increased gene-expression compared to controls; ↓ denotes reduced gene-expression compared to controls. ^¶^Exact number not given by the author.

We next identified, in each cohort, genes that are well known in the sepsis literature (for example, tumour related factor (TNF), interleukin (IL)-1, IL-8, IL-10 and TGF-beta). In particular, we were interested to see whether there was any systematic difference in their expression patterns between cohorts (for example, early sepsis vs. late sepsis). We restricted our analysis to cohorts of comparable microarray platforms (for example, Affymetrix) and target tissues (for example, whole blood). In this analysis, we found no consistent pattern of gene expression in any of the well-established markers of inflammation (pro-inflammatory or anti-inflammatory). Further analyses by stratifying cohorts based on patient groups (paediatric vs. adults) or presentation (pneumonia or non-specified sepsis) yielded similarly negative findings.

Experimental sepsis
-------------------

A major limitation of the above studies is that the findings could be confounded by the variable time from onset of sepsis (since the precise time of infection is often unknown). We, therefore, performed a separate analysis on studies that used an *in vivo*endotoxin challenge model. In these studies, endotoxin was injected into healthy volunteers and blood sampling was performed at regular intervals (up to 24 hours). Consequently, the exact time of onset of infection is known and the effect of timing on gene-expression changes can be clearly defined. We found three endotoxin challenge studies in our data set \[[@B8]-[@B10]\]. All three studies used similar experimental protocols. The analysis showed that endotoxin challenge elicited an activation of pathogen recognition and signal transduction pathways, similar to findings in other non-endotoxemia studies. However, the findings on the inflammatory markers were again conflicting. In one study, a predominantly anti-inflammatory profile was observed \[[@B8]\]. In the other two studies, a mixed profile (anti-inflammatory and pro-inflammatory) was observed \[[@B9],[@B10]\]. Hence, even after allowing for the effect of timing, we still could not find any discernible pattern in inflammation-related genes as described in the classic sepsis model.

Discussion
==========

Historically, cytokine studies suggested that there was a linear transition from pro-inflammatory cytokines to anti-inflammatory cytokines during the course of sepsis. However, these patterns are infrequently seen in clinical settings. In fact, only a few infections follow the classic two-phase model (for example, meningococcal sepsis or contaminated blood transfusions). Recently, studies have shown that inflammatory cytokines in sepsis follow a variable time course \[[@B2],[@B3]\]. Our systematic review extends this growing body of evidence by adding genome-wide data from a variety of clinical settings. In our review, we found that neither a distinctive pro/anti-inflammatory phase nor a clear transition from a pro-inflammatory to anti-inflammatory phase could be seen during sepsis. We also did not observe any discernible pattern in the behaviour of well-established inflammatory markers (for example, TNF-related genes) across the cohorts. Overall, we did not find strong genomic evidence that supports the classic two phase model of sepsis.

The negative finding of our review on the inflammation-related genes is unexpected, considering that the other two well-studied biological phenomena in sepsis, namely the activation of pathogen recognition (for example, toll-like receptors) and signal transduction pathways, are confirmed in most cohorts. The negative finding on inflammation related genes remained even after the cohorts were stratified by timing, patient groups or clinical settings.

The lack of clinical evidence to support the classical two-phase model has been known to many clinicians. The temporal relationship of an early pro-inflammatory phase followed by an anti-inflammatory phase, as depicted in the classical model, is rarely seen in clinical settings. However, this model remains the reigning paradigm under which many anti-sepsis drugs are being developed. The data outlined above therefore provide molecular evidence to validate the increasing concern among clinicians that the current inflammation-based definition of sepsis is too simplistic to describe a complex syndrome \[[@B11]-[@B13]\].

While we did not find evidence to support the inflammation-based model of sepsis, we are not able to rule out the existence of other evidence that may support such a model. This is because of the limitations of our study. For example, our review has excluded other gene-expression studies that did not use microarray platform. As a result, our review is based on data from one particular methodology. Studies using other experimental approaches may repudiate/strengthen our findings. Furthermore, the observed gene-expression changes are restricted to circulating leukocytes. The changes in resident leukocytes in local tissue are likely to be very different from circulating leukocytes. Additional data from resident cells will provide a more complete understanding of the host response to sepsis. Another limitation is that our review does not provide information on changes occurring on a proteomic level, as they are not within the scope of this review. Lastly, most studies did not provide information on the leukocyte differential in the blood sample. The variability in leukocyte differentials could have confounded our findings. Given these several limitations, our findings need to be interpreted with caution. A more thorough evaluation of the sepsis model should involve integrating data from other experimental approaches, including *in vitro*studies, animal models and proteomic data.

Our review also revealed several significant methodological limitations of the current microarray studies in sepsis. First, many of the studies included in our review did not make their raw data publicly available. This makes it difficult for other researchers to verify their findings or to undertake meta-analysis. In addition, each study uses different statistical analysis approaches. In particular, different variance estimation methods were used by studies. However, most studies have adequate sample size; hence the impact of variance estimation on our findings is likely to be minimal. Another notable problem is that authors of each paper present their findings differently, making comparison or generalization of their data difficult. For example, some studies reported only a subset of the discovered genes, while others report functional analyses findings without actually listing the discovered genes. To better utilize the findings derived from gene-expression studies of sepsis, a uniform standard of reporting published microarray findings, such as those required for cancer studies \[[@B6]\], should be considered by all study authors in the future.

Conclusions
===========

Our systematic review shows that sepsis-related inflammatory changes are highly variable on a transcriptional level. The arbitrary distinction of separating sepsis into pro-inflammatory and anti-inflammatory phases is not supported by gene-expression data.

Key messages
============

• Sepsis-related inflammatory changes are highly variable on a transcriptional level.

• These changes are not consistent with the established model of sepsis, where a biphasic pro-inflammatory and anti-inflammatory process is thought to underpin the host response.
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